REN and chronic kidney disease: Drugs that interrupt the renin-angiotensin-aldosterone system (RAAS) are recommended as the preferred antihypertensives because of their additional salutary effects on the progression of CKD (3, 4) and the development of cardiovascular disease (CVD), a major cause of morbidity and mortality in this population (5–7).